The Precipitin Test for Bence-Jones Protein

Collier, Fred C.; Jackson, Paul T.

doi:10.1056/nejm195303052481003

Cited by 18 publications

(8 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Indeed, the translation of mRNA into functional protein is essential to virtually every cellular process and thus is highly regulated, this is especially true for plasma cells, which serves as the central hub of immunoglobulin production. Consistent with our previous findings, the loss of BCMA resulted in the reduction of total human M protein in animals inoculated with human MM tumors, which at high levels, is clinically associated with infections, peripheral neuropathy and bone damages in MM patients (27,47).…”

Section: Discussionsupporting

confidence: 91%

“…Protein translation is a highly regulated given its essential role in every cellular process, this is especially true for plasma cells, which serves as a power house of immunoglobulin production (54). The inhibition of BCMA resulted in the reduction of Ig immunoglobulins, which at high levels, is clinically associated with infections, peripheral neuropathy and bone damages in MM patients (32,55).…”

Section: Discussionmentioning

confidence: 99%

“…1J). Since the presence of M protein signifies the production of dysregulated immunoglobulin proteins in myeloma cells and is a hallmark of MM progression (27), we thought that this observation warranted a further investigation into the potential association between BCMA signaling and protein production and secretion in MM.…”

Section: Bcma Signaling Is Essential For the Growth And Survival Of Multiple Myelomamentioning

confidence: 99%

See 2 more Smart Citations

Developing High-Affinity Decoy Receptor Optimized for Multiple Myeloma and Diffuse Large B Cell Lymphoma Treatment

Miao

Cenik

Jiang

et al. 2021

Preprint

View full text Add to dashboard Cite

B-cell maturation antigen (BCMA) is critical for the viability of Multiple Myeloma (MM) tumor cells and targeting BCMA poses a remarkable opportunity as a potential therapeutic in this cancer. Recent approval of BCMA directed CAR-T and Antibody-Drug-Conjugates (ADCs) have revolutionized MM treatment landscape. Despite such clinical success, treatment resistance and dose limiting toxicity remain as major clinical challenges. Using ribosome profiling, we established a molecular link between BCMA signaling inhibition and protein translation machinery. In addition, BCMA signaling alters the translation efficiency of a transcriptional regulator ATMIN without changing the total mRNA transcript level. Furthermore, ATMIN can transcriptionally regulate IL-6, a critical survival factor for MM. To inhibit the BCMA signaling pathway, we devised both genetic knockdown strategy and pharmacological inhibition by using a soluble BCMA decoy receptor fusion protein (sBCMA-Fc) to trap both of its ligands, APRIL and BAFF. We demonstrated that treatment of MM tumor cells with sBCMA-Fc inhibits tumor progression in numerous in vivo and syngenic PDX tumors models without significant adverse effects. Furthermore, the addition of sBCMA-Fc treatment can restore bortezomib sensitivity in previously bortezomib resistant MM tumors, further adding to its therapeutic value in the treatment of relapse /refractory MM patients. Inhibiting BCMA signaling through neutralization of its ligands APRIL and BAFF with a sBCMA-Fc fusion protein represents a safe and efficacious treatment strategy for the treatment of relapse and refractory MM.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Discussionmentioning

confidence: 99%

Section: Bcma Signaling Is Essential For the Growth And Survival Of Multiple Myelomamentioning

confidence: 99%

See 1 more Smart Citation

Developing High-Affinity Decoy Receptor Optimized for Multiple Myeloma and Diffuse Large B Cell Lymphoma Treatment

Miao

Cenik

Jiang

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…Immunochemical testing is reported to detect it in practically all cases of myeloma (12), and in some cases of other diseases ( 13). * Reginald Maney Lake and Amy Laura Bonamy Research Fellow.…”

mentioning

confidence: 99%